Observational cohort of patients with liver cancer
Official title: Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma
Run by Assistance Publique - Hôpitaux de Paris · NCT04340986 · Data updated 2026-11-12
This study is tracking patients with aggressive liver cancers to see how their treatment and outcomes change over time, hoping to improve their care and find better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1250 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | September 2, 2020 |
| Main results expected | September 2030 |
| Study ends | September 2030 |
| Registry record updated | June 20, 2024 |
| Trial ID | NCT04340986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically or cytologically documented cholangiocarcinoma or hepatocellular carcinoma.
✕Probably not a fit
Patients who do not have a documented diagnosis of cholangiocarcinoma or hepatocellular carcinoma, or those who oppose participation, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect and analyze data from patients diagnosed with hepatocellular carcinoma or cholangiocarcinoma, both of which are aggressive liver cancers. By tracking the evolution of these patients over time, the study seeks to enhance understanding of their care, improve diagnostic and prognostic methods, and identify new therapeutic targets. The research focuses on patients who have been receiving medical care in the nephrology department since 2015, ensuring a comprehensive follow-up of their treatment and outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment strategies and better management of liver cancer patients.
How similar studies have gone: While this approach is observational and builds on existing knowledge, similar studies have shown promise in improving patient outcomes in cancer care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria : * Age ≥ 18 years olds * Medical care in Nephrology department since 2015 Cholangiocarcinoma: \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease Hepatocellular carcinoma: * Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI * Hepatocellular histologically documented Exclusion Criteria: \- Lack of patient non-opposition
Where it's running
-
Serviec hépatologie-Hôpital Saint Antoine
Paris, France Recruiting
Study contacts
- Principal investigator: Marie LEQUOY, MD — AssistancePublique-Hôpitaux de Paris
- Study coordinator: Marie LEQUOY, MD
- Email: marie.lequoy@aphp.fr
- Phone: +330149283154
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy
This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.
-
Using a new imaging agent to detect various cancers
This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.
-
Liquid biopsy to differentiate types of primary liver cancer
This study is testing a new blood test to see if it can tell the difference between two types of liver cancer, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, to help doctors diagnose patients more safely.
-
Navigating Care for Liver Cancer Patients
This study is trying to learn about the experiences of liver cancer patients to create a better support program that helps them and their families manage their care.
-
Evaluating liver embolization techniques for tumor management
This study tests different liver embolization methods to see how well they help people with liver tumors live longer and maintain liver function while they continue their usual treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.